Compositions and methods for t cell engineering

An engineering, cell-based technology, applied in the field of compositions and methods for T cell engineering, capable of solving the problems of time and cost constraints for manufacturing patient-specific T cell products

Pending Publication Date: 2021-09-10
GRACELL BIOTECH SHANGHAI CO LTD +1
View PDF14 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This approach has had early clinical success, but has been limited ...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods for t cell engineering
  • Compositions and methods for t cell engineering
  • Compositions and methods for t cell engineering

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0303] Example 1 Study of U-CAR T cells expressing CD3+CD19 dual CAR and EGFRt switch with TCR knockout

[0304] General Materials and Methods

[0305] Isolation of peripheral blood mononuclear cells (PBMC) and expansion of T cells from donor blood

[0306] Peripheral blood mononuclear cells (PBMCs) were isolated from donor blood by density gradient centrifugation using Histopaque-1077 (Sigma-Aldrich). T cells are then enriched, activated, cultured and expanded by magnetic beads coupled to anti-CD3 / anti-CD28.

[0307] Culture of cell lines and PBMCs

[0308] Raji cells (Burkitt lymphoma cells, ATCC-CCL86);

[0309] K562 cells (human erythroleukemia cell line, ATCC-CCL243);

[0310] Raji-ffluc cell line (obtained by screening Raji cells transfected with lentivirus with firefly luciferase);

[0311] 293T cells (ATCC-CRL3216).

[0312] Raji cells, K562 cells and Raji-ffluc cell line were cultured in RPMI1640 medium, and 293T cells were cultured in DMEM medium. Both RPMI1...

Embodiment 2

[0370] Example 2 Study of U-CAR-T cells expressing CAR19 and enhancer with TCR knockout

[0371] In this example, 5 x 10 5 Raji luciferase cells were transplanted into NOG mice and grown until reaching 100mm 3 . Will 1×10 6 Wild-type or TCR KO CD19 CAR-T cells were infused intravenously (IV) into Raji-transplanted mice. Tumor burden was assessed by caliper measurement of actual tumor size. The expansion of CAR-T cells in peripheral blood was measured by flow cytometry analysis. Figure 8A Tumor burden after CAR-T treatment is shown. TCR intact CD19 CAR-T cells were able to eliminate tumors, but TCR KO CD19 CAR-T could not control Raji tumor growth. Although both are based on Raji's tumor-bearing model, the subcutaneous model produces solid tumors and has higher requirements for tumor-controlled CAR-T cell proliferation than the intravenous model. Figure 8B CAR-T proliferation in peripheral blood is shown. Compared with WT CAR-T cells, TCR KOCAR-T cells showed prolif...

Embodiment 3

[0375] Example 3 has TCR and CD 7 Double-knockout U-CAR-T cells expressing CAR7 and enhancers, and TCR and CD 2 Double knockout expression of CD2 CAR and enhancer U-CAR-T cell research

[0376] General Materials and Methods

[0377] Isolation of peripheral blood mononuclear cells (PBMC) and expansion of T cells from donor blood

[0378] Peripheral blood mononuclear cells (PBMC) were isolated from donor blood by density gradient centrifugation using Histopaque-1077 (Sigma-Aldrich). T cells are then enriched, activated, cultured and expanded by magnetic beads coupled to anti-CD3 / anti-CD28.

[0379] Cell Lines and T Cell Culture

[0380] CCRF-CEM (T lymphoblastoid cells, ) TM

[0381] CCRF-CEM-luc cells (obtained by screening CCRF-CEM cells transfected with lentivirus with firefly luciferase);

[0382] K562 cells (human erythroleukemia cell line, ATCC-CCL243);

[0383] 293T cells (ATCC-CRL3216);

[0384] NK92 cells (ATCC-CRL2407).

[0385] The CCRF-CEM-luc c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The disclosure relates to an engineered immune cell and use thereof. The engineered immune cell provided in the disclosure comprises a CAR or engineered TCR, which CAR or engineered TCR can comprise a first antigen binding domain and a second antigen binding domain. The engineered immune cells, when administered into a subject, can inhibit the host immune cells such as T cells and/or NK cells and enhance the survival and persistence of the engineered immune cells in vivo, thereby exhibiting more effective tumor killing activity.

Description

[0001] cross reference [0002] This application requires Chinese patent application number 201811297174.3 filed on November 1, 2018; Chinese patent application number 201811535338.1 filed on December 14, 2018; Chinese patent application number 201811549651.0 filed on December 18, 2018; June 6, 2019 Chinese Patent Application No. 201910492882.0, filed on 2019; and PCT Application No. PCT / CN2019 / 101651, filed on August 20, 2019, each of which is incorporated herein by reference in its entirety. Background technique [0003] Genetic modification to express chimeric antigen receptors (CARs) to generate tumor-specific T lymphocytes is gaining attention as a form of synthetic biology that produces potent antitumor effects. Since specificity is conferred by antibody fragments, CAR-T cells are not MHC-restricted and thus more practical than approaches based on T-cell receptors that require MHC-matching. [0004] Although early clinical data on CAR-T cells in cancer treatment have sh...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C12N5/10C12N15/85A61K35/17A61P35/00
CPCA61P35/00A61K35/17C12N2510/00C12N5/0636C12N2503/00C07K14/7051C12N15/90C12N2740/16043A61K48/005C07K2319/03C07K16/2803C07K16/2878C07K2317/31A61K2039/5156A61K35/28A61K35/545C12N2310/20C12N15/1138A61K39/001112A61K39/001102A61K2039/5158C12N2501/515C12N2501/2307A61K2039/804A61K2239/48A61K2239/28A61K39/464412A61K39/464419A61K39/46444A61K39/0011C07K14/71C07K14/70596C07K16/2809C07K2319/02C07K2317/622A61K38/00C07K14/70507
Inventor 王欣欣金涛杨春辉施中东刘丽萍孙静邱淑怡曹卫
Owner GRACELL BIOTECH SHANGHAI CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap